Cardiovascular Indications and Complications of Recombinant Human Erythropoietin

Abstract

Vekaria A, Gigani Y, Belemkar S

Exogenous recombinant human erythropoietin (rHuEPO) is a beneficial therapeutic agent for correction of anemia in chronic kidney disease (CKD), end-stage renal disease, chemotherapy, and has been used as prophylaxis to prevent anemia after surgery. The erythropoietin receptor is widely distributed in the cardiovascular system, including endothelial cells, smooth muscle cells and cardiomyocytes. RHuEPO has potentially beneficial effects on the endothelium including cytoprotective, mitogenic and angiogenic activities. Early studies in heart failure patients with anemia suggest that rHuEpo therapy is safe and effective in reducing left ventricular hypertrophy, enhancing exercise performance and increasing ejection fraction. The use of rHuEPO, however, may also be associated with distinct side effects. Although not clearly demonstrated, a relationship between an increased red blood cell count and thrombus formation. Some reports suggest that rHuEpo may have prothrombotic or alters platelet aggregatory responses. Most notable is hypertension (HTN), partial correction of anemia with intravenous rHuEPO causes HTN. CREATE study found a trend toward increased mortality risk with a higher Hb target of 13-15 g/dl. Therefore aiming for a higher hematocrit level is still a controversial issue in the management of anemia in renal failure. Despite some potential adverse effect.

How to Cite this Article
Pubmed Style

Vekaria A, Gigani Y, Belemkar S. Cardiovascular Indications and Complications of Recombinant Human Erythropoietin. SRP. 2011; 2(1): 43-47.
doi:10.4103/0975-8453.83438

Web Style

Vekaria A, Gigani Y, Belemkar S. Cardiovascular Indications and Complications of Recombinant Human Erythropoietin. http://www.sysrevpharm.org/?mno=302644610 [Access: March 28, 2021]. doi:10.4103/0975-8453.83438

AMA (American Medical Association) Style

Vekaria A, Gigani Y, Belemkar S. Cardiovascular Indications and Complications of Recombinant Human Erythropoietin. SRP. 2011; 2(1): 43-47. doi:10.4103/0975-8453.83438



Vancouver/ICMJE Style

Vekaria A, Gigani Y, Belemkar S. Cardiovascular Indications and Complications of Recombinant Human Erythropoietin. SRP. (2011), [cited March 28, 2021]; 2(1): 43-47. doi:10.4103/0975-8453.83438



Harvard Style

Vekaria A, Gigani Y, Belemkar S (2011) Cardiovascular Indications and Complications of Recombinant Human Erythropoietin. SRP, 2 (1), 43-47. doi:10.4103/0975-8453.83438



Turabian Style

Vekaria A, Gigani Y, Belemkar S. 2011. Cardiovascular Indications and Complications of Recombinant Human Erythropoietin. Systematic Reviews in Pharmacy, 2 (1), 43-47. doi:10.4103/0975-8453.83438



Chicago Style

Vekaria A, Gigani Y, Belemkar S. "Cardiovascular Indications and Complications of Recombinant Human Erythropoietin." Systematic Reviews in Pharmacy 2 (2011), 43-47. doi:10.4103/0975-8453.83438



MLA (The Modern Language Association) Style

Vekaria A, Gigani Y, Belemkar S. "Cardiovascular Indications and Complications of Recombinant Human Erythropoietin." Systematic Reviews in Pharmacy 2.1 (2011), 43-47. Print. doi:10.4103/0975-8453.83438



APA (American Psychological Association) Style

Vekaria A, Gigani Y, Belemkar S (2011) Cardiovascular Indications and Complications of Recombinant Human Erythropoietin. Systematic Reviews in Pharmacy, 2 (1), 43-47. doi:10.4103/0975-8453.83438

Most Viewed Articles
  • Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli SRP. 2020; 11(1): 01-06 » doi: 10.5530/srp.2020.1.01
  • Psychometric properties of the World Health Organization Quality of life instrument, short form: Validity in the Vietnamese healthcare context Trung Quang Vo*, Bao Tran Thuy Tran, Ngan Thuy Nguyen, Tram ThiHuyen Nguyen, Thuy Phan Chung Tran SRP. 2020; 11(1): 14-22 » doi: 10.5530/srp.2019.1.3
  • A Review of Pharmacoeconomics: the key to “Healthcare for All” Hasamnis AA, Patil SS, Shaik Imam, Narendiran K SRP. 2019; 10(1): s40-s42 » doi: 10.5530/srp.2019.1s.21
  • Deuterium Depleted Water as an Adjuvant in Treatment of Cancer Anton Syroeshkin, Olga Levitskaya, Elena Uspenskaya, Tatiana Pleteneva, Daria Romaykina, Daria Ermakova SRP. 2019; 10(1): 112-117 » doi: 10.5530/srp.2019.1.19
Most Downloaded
  • Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli SRP. 2020; 11(1): 01-06 » doi: 10.5530/srp.2020.1.01
  • Manilkara zapota (L.) Royen Fruit Peel: A Phytochemical and Pharmacological Review Karle Pravin P, Dhawale Shashikant C SRP. 2019; 10(1): 11-14 » doi: 0.5530/srp.2019.1.2
  • Pharmacognostic and Phytopharmacological Overview on Bombax ceiba Pankaj Haribhau Chaudhary, Mukund Ganeshrao Tawar SRP. 2019; 10(1): 20-25 » doi: 10.5530/srp.2019.1.4
  • A Review of Pharmacoeconomics: the key to “Healthcare for All” Hasamnis AA, Patil SS, Shaik Imam, Narendiran K SRP. 2019; 10(1): s40-s42 » doi: 10.5530/srp.2019.1s.21
  • A Prospective Review on Phyto-Pharmacological Aspects of Andrographis paniculata Govindraj Akilandeswari, Arumugam Vijaya Anand, Palanisamy Sampathkumar, Puthamohan Vinayaga Moorthi, Basavaraju Preethi SRP. 2019; 10(1): 15-19 » doi: 10.5530/srp.2019.1.3